About Proteomics International
Proteomics International is a company based in Perth (Australia) founded in 2001 by Richard Lipscombe. Proteomics International offers products and services including PromarkerD, PromarkerEndo, PromarkerEso, and OxiDx. Proteomics International operates in a competitive market with competitors including Metabolon, Maze Therapeutics, Alector, Seer and Tango Therapeutics, among others.
- Headquarter Perth, Australia
- Founders Richard Lipscombe
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Proteomics International Laboratories Ltd
-
Annual Revenue
$627.13 K (USD)7.65as on Jun 30, 2025
-
Net Profit
-$5.3 M (USD)-27.27as on Jun 30, 2025
-
EBITDA
-$6.48 M (USD)-21.4as on Jun 30, 2025
-
Latest Funding Round
$4.28 M (USD), Post-IPO
Jan 23, 2024
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Proteomics International
Proteomics International is a publicly listed company on the ASX with ticker symbol PIQ in Australia, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Proteomics International
Proteomics International offers a comprehensive portfolio of products and services, including PromarkerD, PromarkerEndo, PromarkerEso, and OxiDx.
Predictive test for diabetic kidney disease detection
Blood test for endometriosis diagnosis accuracy
Esophageal cancer diagnostic with high accuracy
Tool for oxidative stress analysis in health research
People of Proteomics International
Unlock access to complete
Unlock access to complete
Funding Insights of Proteomics International
Investors in Proteomics International
Proteomics International has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include MTPConnect.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Australia's life sciences innovation is accelerated by MTPConnect.
|
Locked | Locked | Locked |
Investor details for Proteomics International
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Proteomics International
Investment portfolio details for Proteomics International
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Proteomics International
Detailed financials for Proteomics International
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Proteomics International Comparisons
Peer comparison for Proteomics International
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Proteomics International
Proteomics International operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Metabolon, Maze Therapeutics, Alector, Seer and Tango Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Solutions for biomarker discovery and diagnostic testing are provided.
|
|
| Locked | Locked | Locked |
Genetic biomarkers are developed for neurological, metabolic, and renal diseases.
|
|
| Locked | Locked | Locked |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed.
|
|
| Locked | Locked | Locked |
Proteomics platform developed for early cancer and neurological disease detection.
|
|
| Locked | Locked | Locked |
Novel cancer drugs are developed using synthetic lethality screening.
|
|
| Locked | Locked | Locked |
NeoPhore is focused on cancer neoantigen evolution therapies.
|
Detailed competitors of Proteomics International
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Proteomics International
Complete news archive for Proteomics International
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Proteomics International
Proteomics International was founded in 2001 and raised its 1st funding round 11 years after it was founded.
Proteomics International is headquartered in Perth, Australia. It is registered at Perth, Western Australia, Australia.
Annual revenue of Proteomics International is $627.13K as on Jun 30, 2025.
Medical technology company at the forefront of predictive diagnostics and bio-analytical services. The company develop and commercializes diagnostic tests known as PromarkerD, for the detection of diabetic kidney disease. Company specialises in the area of proteomics, the industrial scale study of the structure and function of proteins. It also, offers analytical services for research purposes. The technology can be used to identify fingerprints from any biological source, from wheat seeds to human serum.
Proteomics International's top competitors include Alector, Lexicon Pharmaceuticals and Maze Therapeutics.
Proteomics International offers PromarkerD, PromarkerEndo, PromarkerEso, and OxiDx.
Yes, Proteomics International is publicly traded on ASX under the ticker symbol PIQ.
Proteomics International has 1 investor. Key investors include MTPConnect.
The ticker symbol of Proteomics International is PIQ on ASX.